Previous 10 | Next 10 |
HOUSTON , Sept. 24, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today ...
HOUSTON , Sept. 19, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today ...
HOUSTON , Sept. 17, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today ann...
HOUSTON , Sept. 10, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today ann...
HOUSTON , Sept. 9, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced...
HOUSTON , Sept. 4, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced...
HOUSTON , Aug. 29, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today anno...
HOUSTON , Aug. 26, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today anno...
Soliton ( SOLY +17.8% ) is up on below-average volume in response to new preclinical data supporting longer treatment times with its Rapid Acoustic Pulse (RAP) device aimed at improving the appearance of cellulite. More news on: Soliton, Inc., Healthcare stocks news, Stocks on the move...
Nabriva Therapeutics plc (NASDAQ: NBRV ) +23% . More news on: Nabriva Therapeutics plc, VIVUS, Inc., Seadrill Limited, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Allergan Aesthetics Completes Acquisition of Soliton -- Addition of Soliton complements Body Contouring Portfolio with expansion to treat appearance of cellulite -- PR Newswire IRVINE, Calif. , Dec. 16, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie comp...
On a gloomy day for the stock market, healthcare aesthetics specialist Soliton (NASDAQ: SOLY) was a luminous bright spot on Tuesday. The company's shares rocketed almost 12% higher, on news that its absorption into soon-to-be-parent AbbVie (NYSE: ABBV) is about to close. ...
Soliton Inc. (NASDAQ:SOLY) traded today at a new 52-week high of $22.60. So far today approximately 147,000 shares have been exchanged, as compared to an average 30-day volume of 103,000 shares. Based on a current price of $22.53, Soliton Inc. is currently 19.0% above its average consens...